Finding great science and building promising startups to deliver better medicines for patients.

Dr. Marianna Feretzaki joined Biomed in 2026 with a background in drug discovery and biotechnology innovation.

Prior to Biomed, Marianna was Scientific Director and CEO a.i. at Rejuveron Telomere Therapeutics in Zurich, where she led scientific strategy and managed collaborations with CROs, academic partners and investors. Previously, she served as Head of Discovery Biology at Rejuveron, leading preclinical programs and supporting scientific and business due diligence for new therapeutic opportunities.

Earlier in her career, Marianna conducted academic research at leading international institutions. During this time, she was awarded a Marie Skłodowska-Curie Individual Fellowship for her postdoctoral research and received an NIH-funded CFAR grant during her PhD.

Marianna holds a PhD in Genetics and Genomics from Duke University and a bachelor’s degree in biology from the University of Crete. She is the author of several publications in international scientific journals, including Nature and EMBO Journal.

Dr. Morgan Hunter joined Biomed in 2022 with a background in scientific innovation and early entrepreneurship.
Prior to Biomed, Morgan initiated and developed the business case for the planned ETH Zurich spin-off Emuna Therapeutics (CEO/CSO role), leading an Innosuisse Innovation Project and as an SNF BRIDGE Proof of Concept Fellow.

Morgan holds a Doctor of Sciences from ETH Zurich specializing in pharmaceutical immunology, vascular biology, and protein/antibody engineering; a Master of Science in Biochemistry from Rhodes University (South Africa); and a Financial Modelling and Valuation Analyst (FMVA)® certification from the Corporate Finance Institute (CFI).

Dr. Aristotelis Nastos joined Biomed as Managing Partner in 2023 and has a long-standing career in the European venture capital industry. During this time, he has been involved in numerous financing rounds as well as several trade sales. Before joining Biomed, he worked at NRW.BANK in Düsseldorf as Head of Life Sciences, where he was responsible for a portfolio of a total of 35 companies. He also served on the boards of several of these companies, including Emergence (sold to Lilly in 2023), CEVEC (sold to Cytiva in 2022), Scienion (sold to Cellink/BICO in 2020), Rigontec (sold to MSD in 2017), and Direvo (sold to Bayer in 2008).

He began his venture capital career at Peppermint in Berlin and later also served as a Partner at Creathor Ventures in Bad Homburg.

Telis holds a degree in Biology and completed his PhD at the Institute for Cell Biology at the University Hospital in Essen. He subsequently received a Wellcome International Research Fellowship and moved to King’s College London for a postdoctoral position. During his academic career, he also served as Head of a research group at the German Diabetes Research Center in Düsseldorf.